Board of Directors of Artgen Biotech canceled the shareholders' meeting, which was supposed to resolve the issue of increasing the authorized capital by 7.5% by placing additional shares. At the same time, the Board of Directors itself decided to place 17,354,549 additional shares of the company by public subscription in 2024. Raised funds as a result of the additional share issue are planned to be used for development and expansion of the development portfolio and production base in 2024-2026.